Literature DB >> 19170050

A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.

Marco Bonetti1, David Zahrieh, Bernard F Cole, Richard D Gelber.   

Abstract

A new, intuitive method has recently been proposed to explore treatment-covariate interactions in survival data arising from two treatment arms of a clinical trial. The method is based on constructing overlapping subpopulations of patients with respect to one (or more) covariates of interest and in observing the pattern of the treatment effects estimated across the subpopulations. A plot of these treatment effects is called a subpopulation treatment effect pattern plot. Here, we explore the small sample characteristics of the asymptotic results associated with the method and develop an alternative permutation distribution-based approach to inference that should be preferred for smaller sample sizes. We then describe an extension of the method to the case in which the pattern of estimated quantiles of survivor functions is of interest.

Entities:  

Mesh:

Year:  2009        PMID: 19170050      PMCID: PMC2843827          DOI: 10.1002/sim.3524

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  Detecting treatment-by-centre interaction in multi-centre clinical trials.

Authors:  R F Potthoff; B L Peterson; S L George
Journal:  Stat Med       Date:  2001-01-30       Impact factor: 2.373

2.  A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.

Authors:  M Bonetti; R D Gelber
Journal:  Stat Med       Date:  2000-10-15       Impact factor: 2.373

3.  Statistics in medicine--reporting of subgroup analyses in clinical trials.

Authors:  Rui Wang; Stephen W Lagakos; James H Ware; David J Hunter; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

4.  Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.

Authors:  M Colleoni; S Li; R D Gelber; A S Coates; M Castiglione-Gertsch; K N Price; J Lindtner; C-M Rudenstam; D Crivellari; J Collins; O Pagani; E Simoncini; B Thürlimann; E Murray; J Forbes; D Erzen; S Holmberg; A Veronesi; A Goldhirsch
Journal:  Ann Oncol       Date:  2005-04-07       Impact factor: 32.976

5.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

6.  Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

Authors:  Monica Castiglione-Gertsch; Anne O'Neill; Karen N Price; Aron Goldhirsch; Alan S Coates; Marco Colleoni; M Laura Nasi; Marco Bonetti; Richard D Gelber
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

7.  Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

Authors:  Diana Crivellari; Karen Price; Richard D Gelber; Monica Castiglione-Gertsch; Carl-Magnus Rudenstam; Jurij Lindtner; Martin F Fey; Hans-Jörg Senn; Alan S Coates; John Collins; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Patterns of treatment effects in subsets of patients in clinical trials.

Authors:  Marco Bonetti; Richard D Gelber
Journal:  Biostatistics       Date:  2004-07       Impact factor: 5.899

9.  Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.

Authors:  M Colleoni; H J Litman; M Castiglione-Gertsch; W Sauerbrei; R D Gelber; M Bonetti; A S Coates; M Schumacher; G Bastert; C-M Rudenstam; C Schmoor; J Lindtner; J Collins; B Thürlimann; S B Holmberg; D Crivellari; C Beyerle; R L A Neumann; A Goldhirsch
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

  9 in total
  13 in total

1.  A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.

Authors:  Silvia Dellapasqua; Vincenzo Bagnardi; Meredith M Regan; Nicole Rotmensz; Mauro G Mastropasqua; Giuseppe Viale; Eugenio Maiorano; Karen N Price; Richard D Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Marco Colleoni
Journal:  Breast       Date:  2012-06-29       Impact factor: 4.380

2.  Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy.

Authors:  Dan Li; Chenhan Zhong; Xiujun Tang; Linzhen Yu; Kefeng Ding; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-19       Impact factor: 4.553

3.  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Authors:  Antonio C Wolff; Ann A Lazar; Igor Bondarenko; August M Garin; Stephen Brincat; Louis Chow; Yan Sun; Zora Neskovic-Konstantinovic; Rodrigo C Guimaraes; Pierre Fumoleau; Arlene Chan; Soulef Hachemi; Andrew Strahs; Maria Cincotta; Anna Berkenblit; Mizue Krygowski; Lih Lisa Kang; Laurence Moore; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

4.  Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.

Authors:  Ann A Lazar; Bernard F Cole; Marco Bonetti; Richard D Gelber
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

5.  CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.

Authors:  Katrín A Gunnarsdóttir; Maj-Britt Jensen; David Zahrieh; Richard D Gelber; Ann Knoop; Marco Bonetti; Henning Mouridsen; Bent Ejlertsen
Journal:  Breast Cancer Res Treat       Date:  2010-05-13       Impact factor: 4.872

6.  The prognostic effect of HER2 heterogeneity and YAP1 expression in HER2 positive breast cancer patients: a retrospective study.

Authors:  Jia-Qi Yuan; Zhi Xiao; Shou-Man Wang; Lei Guo
Journal:  Gland Surg       Date:  2022-02

7.  Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials.

Authors:  Willi Sauerbrei; Patrick Royston
Journal:  BMC Med Res Methodol       Date:  2022-04-06       Impact factor: 4.615

8.  Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.

Authors:  Wai-Ki Yip; Marco Bonetti; Bernard F Cole; William Barcella; Xin Victoria Wang; Ann Lazar; Richard D Gelber
Journal:  Clin Trials       Date:  2016-04-19       Impact factor: 2.486

9.  Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.

Authors:  Ann A Lazar; Marco Bonetti; Bernard F Cole; Wai-Ki Yip; Richard D Gelber
Journal:  Clin Trials       Date:  2015-10-22       Impact factor: 2.486

10.  Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.

Authors:  Jan Budczies; Frederick Klauschen; Bruno V Sinn; Balázs Győrffy; Wolfgang D Schmitt; Silvia Darb-Esfahani; Carsten Denkert
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.